(+/-)-KWD 2109 | 127560-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (+/-)-KWD 2109
• 英文别名: Norbudrine；4-[2-(cyclobutylamino)-1-hydroxyethyl]benzene-1,2-diol
• CAS: 127560-12-7
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: OVTZNVCECJYMDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
  申请人：Astion Development A/S

  公开号：EP1719507A1

  公开（公告）日：2006-11-08

  The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.

  本发明提供了治疗皮肤结缔组织疾病，特别是治疗红斑狼疮皮肤病的有效而安全的药物。这些药物包括作为治疗活性成分的β2肾上腺素受体激动剂。此外，本发明还涉及不具有皮肤过敏特性的皮肤病治疗组合物，该组合物含有对映体纯的或β2肾上腺素受体激动剂的富集R-对映体。
• Treatment of connective tissue diseases of the skin
  申请人：Weidner Sloth Morten

  公开号：US20060235048A1

  公开（公告）日：2006-10-19

  The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta 2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta 2 adrenoceptor agonist.

  本发明提供了治疗皮肤结缔组织疾病，特别是治疗红斑狼疮皮肤病的有效而安全的药物。这些药物包括作为治疗活性成分的 beta 2 肾上腺素受体激动剂。此外，本发明还涉及不具有皮肤过敏特性的皮肤病治疗组合物，该组合物含有对映体纯度高或富含 R-对映体的 β2-肾上腺素受体激动剂。 2 肾上腺素受体激动剂。
• A POLYMER PRODUCT AND PREPARATION THEREOF
  申请人：Singapore Health Services Pte Ltd

  公开号：EP3319779A1

  公开（公告）日：2018-05-16
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.